The core of THE CORE—its primary drug assessment platform—is the Kirchhoff Family Drug Screening Unit, where CORE researchers develop new cellular models of ALS, and

The current issue of Neuroscience journal is dedicated to the staggering contributions to science made by longtime Project ALS Research Advisory Board Chair Thomas M. Jessell, PhD, before his death from the rare neurodegenerative disease progressive supranuclear palsy on April 28, 2019, at 67.

While COVID-19 profoundly affected its day-to-day operations, The Project ALS Therapeutics Core at Columbia generated new approaches to disease modeling and genetic engineering technologies in 2020.

Project ALS, along with the rest of the world, has faced serious headwinds this year—but we regrouped, focused our priorities, and have taken significant strides

The key to finding better drugs at the Project ALS Therapeutics Core at Columbia (THE CORE) is developing better pre-clinical laboratory models of ALS. A

Earlier this month, we reached a big regulatory milestone: Prosetin received Orphan Drug Designation, or orphan status, for the treatment of ALS from the Food